Figure 2.

N/OFQ inhibits bronchial hyperreponsiveness. (A) In vivo experimental protocol: N/OFQ administered 30 min prior to OVA challenge (N/OFQ post‐OVA sensitization); (B) in vivo experimental protocol: N/OFQ administered 30 min prior to OVA‐sensitization (N/OFQ pre‐OVA sensitization); (C) representative image of N/OFQ (green) qualitative and quantitative expression in vivo by immunofluorescence, scale bars 20 μm; (D) measurement of ACh‐induced lung resistance in an in vivo model (N/OFQ post‐OVA sensitization) with AUC (inset, n = 6 mice); and (E) measurement of ACh‐induced lung resistance in an in vivo model (N/OFQ pre‐OVA sensitization) with AUC (inset), n = 4 mice. Data are expressed as mean ± SEM. Statistical comparisons by one‐way or two‐way anova followed by appropriate post hoc tests where relevant *P <0.05. N/OFQ administered at 1 μM is equivalent to 15 μg·kg⁻¹.